Cevimeline

Overview
Cevimeline (commercially known as Evoxac) is a synthetic muscarinic receptor agonist developed for the treatment of xerostomia (dry mouth) associated with Sjögren’s syndrome. It acts by stimulating muscarinic cholinergic receptors in exocrine glands, thereby enhancing salivary secretion. The United States Food and Drug Administration (FDA) approved cevimeline for this indication in 1997.

Chemical properties

• IUPAC name: (R)-N‑[(1R,2S,3R,4S)-3‑hydroxy‑1‑phenyl‑3‑(4‑hydroxyphenyl)butyl]‑1‑phenyl‑2‑pyrrolidinecarboxamide
• Molecular formula: C₂₀H₂₇NO₃
• Molecular weight: 321.42 g·mol⁻¹
• Physical form: White to off‑white crystalline powder; supplied as the hydrochloride salt for oral administration.

Pharmacodynamics
Cevimeline is a parasympathomimetic that binds to muscarinic acetylcholine receptors, with relative selectivity for the M₁, M₃, and M₅ subtypes. Activation of these receptors in salivary and lacrimal glands stimulates secretion of saliva and tears. It exhibits a higher affinity for M₃ receptors, which mediate glandular secretory functions, than for the cardiac‑dominant M₂ subtype, thereby reducing the likelihood of significant cardiac side effects at therapeutic doses.

Pharmacokinetics

• Absorption: Rapid oral absorption; peak plasma concentrations occur within 1–2 hours post‑dose.
• Distribution: Approximately 70 % plasma protein binding.
• Metabolism: Primarily hepatic via oxidative pathways (CYP3A4 contributes modestly).
• Elimination: Renal excretion of unchanged drug and metabolites; terminal half‑life ≈ 4 hours.

Therapeutic indication

• Primary use: Management of xerostomia in adult patients with primary or secondary Sjögren’s syndrome.
• The drug is not indicated for other forms of dry mouth (e.g., medication‑induced) unless prescribed off‑label by a qualified clinician.

Dosage and administration

• Standard adult regimen: 30 mg orally three times daily (morning, midday, evening), taken with water.
• Dose adjustments are recommended in patients with moderate to severe renal impairment (eGFR < 30 mL/min/1.73 m²) or hepatic dysfunction.

Contraindications

• Known hypersensitivity to cevimeline or any excipients.
• Active asthma or chronic obstructive pulmonary disease (COPD) where cholinergic stimulation may exacerbate bronchospasm.
• Uncontrolled narrow‑angle glaucoma.
• Gastrointestinal obstruction or severe ulcer disease.

Adverse effects
Common (≥ 5 %):

• Sweating, increased urinary frequency, nausea, abdominal cramps, diarrhoea, headache, dizziness.

Less common but clinically relevant:

• Bradycardia, hypotension, bronchospasm, exacerbation of peptic ulcer disease, hepatic enzyme elevations.

Drug interactions

• Anticholinergic agents (e.g., atropine, antihistamines) may antagonize the therapeutic effect of cevimeline.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) can increase plasma concentrations; dose reduction may be required.
• Beta‑adrenergic agonists used for asthma may have reduced efficacy when combined with cevimeline due to opposing bronchomotor effects.

Safety in pregnancy and lactation
Animal studies have not demonstrated teratogenicity, but adequate and well‑controlled human data are lacking. Cevimeline is classified as Pregnancy Category C in the United States; it should be used only if the potential benefit justifies the potential risk to the fetus. Excretion in human milk is expected; caution is advised when breastfeeding.

Regulatory status

• United States: Prescription‑only (Rx), FDA‑approved.
• European Union: Marketed under the brand name Evoxac in several member states; requires a prescription.
• Other jurisdictions: Available in Canada, Japan, and several Asian markets under comparable regulatory frameworks.

History
Cevimeline was discovered in the early 1990s by a collaborative effort among pharmaceutical researchers seeking selective muscarinic agonists to address salivary gland hypofunction. Clinical trials demonstrated dose‑dependent increases in stimulated salivary flow without severe cholinergic toxicity, leading to FDA approval for the specific indication of Sjögren’s‑associated xerostomia.

Society and culture
The drug’s introduction provided the first disease‑specific pharmacologic option for a condition previously managed largely by saliva substitutes and mechanical stimulants (e.g., sugar‑free chewing gum). Its use remains limited to patients with confirmed Sjögren’s syndrome due to cost considerations and the modest magnitude of salivary flow increase relative to baseline.

Research directions
Ongoing investigations explore cevimeline’s potential benefits in other autonomic dysfunctions, such as neurogenic bladder disorders, though no additional indications have received regulatory approval as of the latest literature.

All information presented reflects data available from peer‑reviewed pharmacology texts, FDA labeling, and major drug reference compendia up to July 2026.